Takeda Pharmaceutical Company
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries.
Current Price
$16.68
+0.60%GoodMoat Value
$44.87
169.0% undervaluedTakeda Pharmaceutical Company (TAK) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Takeda Pharmaceutical Company's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $29.80B. Gross profit (TTM) is $19.46B. EBITDA is $8.78B. Earnings per share (EPS) is $0.23. The P/E ratio is 73.27. Market capitalization is $52.11B.
Free cash flow (FCF) is $5.44B. FCF growth rate is 0.92%. EPS growth CAGR is 19.61%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY20 to FY26. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Takeda Pharmaceutical Company's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
